Published in Nat Med on January 01, 1998
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
The glycosynapse. Proc Natl Acad Sci U S A (2002) 2.46
A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother (2009) 1.75
Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol (2014) 1.49
MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol (2008) 1.38
Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol (2014) 1.00
Natural and Induced Humoral Responses to MUC1. Cancers (Basel) (2011) 0.93
MUC1 in carcinoma-host interactions. Glycoconj J (2001) 0.92
Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol (2006) 0.91
MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism. Biochim Biophys Acta (2007) 0.90
Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunology (2003) 0.90
Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients. Br J Cancer (1999) 0.89
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer (2010) 0.88
Lung cancer vaccines: current status and future prospects. Transl Lung Cancer Res (2014) 0.86
MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form. J Clin Pathol (2001) 0.85
Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2. J Biomed Biotechnol (2003) 0.85
Peroxisome proliferator-activated receptor gamma activation inhibits progesterone-stimulated human MUC1 expression. Mol Endocrinol (2010) 0.84
Mucinous cystic carcinoma of the pancreas: a unique cell line and xenograft model of a preinvasive lesion. Virchows Arch (2005) 0.84
A novel cell line and xenograft model of ampulla of Vater adenocarcinoma. Virchows Arch (2003) 0.83
Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy. PLoS One (2014) 0.83
Lung cancer vaccines. Cancer J (2011) 0.82
Immunotherapy in lung cancer. Transl Lung Cancer Res (2014) 0.82
Transmembrane mucins as novel therapeutic targets. Expert Rev Endocrinol Metab (2011) 0.82
Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors. Clin Exp Metastasis (2003) 0.80
Cancer stem cells and immunoresistance: clinical implications and solutions. Transl Lung Cancer Res (2015) 0.79
A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1. Br J Cancer (2000) 0.79
Immune selection in neoplasia: towards a microevolutionary model of cancer development. Br J Cancer (2000) 0.79
Trends and advances in tumor immunology and lung cancer immunotherapy. J Exp Clin Cancer Res (2016) 0.78
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. BMC Cancer (2012) 0.78
No evidence for MUC 1-induced apoptosis. Nat Med (1998) 0.77
Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients. Clin Exp Metastasis (2004) 0.76
Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients. Oncoimmunology (2015) 0.76
Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumour-reactive T-cells. Br J Cancer (2000) 0.75
Comparison of immunohistochemistry with conventional histopathology for evaluation of sentinel lymph node in breast cancer. Indian J Surg (2010) 0.75
Significance of Proline Residue on Short Mucin Peptide Interactions with Mouse MUC1 Monoclonal Antibody Studied by Saturation Transfer Difference NMR Spectroscopy. JSM Chem (2013) 0.75
Assessment of tumor characteristics based on glycoform analysis of membrane-tethered MUC1. Lab Invest (2017) 0.75
2-Imino-2-methoxyethyl 1-thioglycosides: new reagents for attaching sugars to proteins. Biochemistry (1976) 2.18
Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. Blood (1992) 1.88
Murine T-cell clones specific for chicken erythrocyte alloantigens. Cell Immunol (1986) 1.77
Attachment of thioglycosides to proteins: enhancement of liver membrane binding. Biochemistry (1976) 1.41
Biochemical and immunological characterization of the major envelope glycoprotein gp69/71 and degradation fragments from Rauscher leukemia virus. J Virol (1977) 1.37
Dopamine-beta-hydroxylase: a tetrameric glycoprotein. Proc Natl Acad Sci U S A (1973) 1.33
Analysis of Halobacterium halobium gas vesicles. J Bacteriol (1973) 1.29
The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res (1996) 1.24
Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res (1998) 1.20
Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother (1993) 1.15
Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers. J Natl Cancer Inst (1987) 1.15
Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol (1996) 1.13
Tumor cell surface alpha 4 beta 1 integrin mediates adhesion to vascular endothelium: demonstration of an interaction with the N-terminal domains of INCAM-110/VCAM-1. Cell Regul (1991) 1.10
GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res (1995) 1.09
Nomenclature for chicken major histocompatibility (B) complex. Immunogenetics (1982) 1.08
Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells. Cancer Immunol Immunother (1999) 1.06
A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer (1996) 1.03
Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol (1996) 1.03
Quantitative hydrolysis of thioglycosides. Anal Biochem (1976) 1.02
Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer (1998) 1.01
Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res (1990) 1.01
Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother (1996) 1.00
Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res (1995) 0.99
Characterization and comparison of the major glycoprotein from three strains of Rous sarcoma virus. Arch Biochem Biophys (1976) 0.98
The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol Med Today (1998) 0.97
Epitopes of carcinoembryonic antigen defined by monoclonal antibodies prepared from mice immunized with purified carcinoembryonic antigen or HCT-8R cells. Cancer Res (1986) 0.97
"Natural" antibodies to chicken MHC antigens are present in mice, rats, humans, alligators and allogeneic chickens. Immunogenetics (1980) 0.96
Immune response of the mouse to gram-negative bacterial outer membrane extracts as assessed with monoclonal antibodies. J Immunol (1982) 0.96
The role of the bursa Fabricius, spleen and thymus in the control of a Plasmodium lophurae infection in the chicken. J Immunol (1966) 0.96
Characteristics of JMV Marek's disease tumor: a nonproductively infected transplantable cell lacking in rescuable Virus. J Natl Cancer Inst (1976) 0.96
A monoclonal antibody detecting a 39,000 m.w. molecule that is present on B lymphocytes and chronic lymphocytic leukemia cells but is rare on acute lymphocytic leukemia blasts. J Immunol (1983) 0.96
Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa. Glycoconj J (1998) 0.95
Radioimmunotechnology for cancer diagnosis and treatment. Can Med Assoc J (1983) 0.95
Comparison of the 40 kDa hematopoietic cell antigens bound by monoclonal antibodies IV.3, 41H.16 and KB61. Mol Immunol (1989) 0.95
Immunoglobulin-secreting cells recovered from rejected human renal allografts. Transplantation (1982) 0.95
Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant (2000) 0.93
CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors. J Immunol (1996) 0.93
Does pregnancy immunize against breast cancer? Cancer Res (1995) 0.93
Tumour markers in the detection of opisthorchiasis-associated cholangiocarcinoma. Trans R Soc Trop Med Hyg (1991) 0.92
Genetic control of graft-versus-host competence. Transplantation (1972) 0.92
Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Glycoconj J (1997) 0.92
MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj J (2003) 0.91
Natural and acquired antibodies to Plasmodium lophurae in intact and bursaless chickens. II. Immunofluorescent studies. J Parasitol (1969) 0.90
Measurement of graft-versus-host reactions on the chorioallantoic membrane of the chicken. Transplantation (1970) 0.89
A monoclonal antibody specific for the Thomsen-Friedenreich cryptic T antigen. J Immunol (1982) 0.89
Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim Biophys Acta (2001) 0.89
Carbohydrate determinants associated with carcinoembryonic antigen (CEA). J Immunol (1985) 0.88
Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2-->6) T antigens. Hybridoma (1996) 0.87
Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int J Cancer (1998) 0.87
Structure and properties of the major histocompatibility complex of the chicken. Speculations on the advantages and evolution of polymorphism. Immunogenetics (1981) 0.87
In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol (1996) 0.87
Clonal variation and functional correlation of organ-specific metastasis and an organ-specific metastasis-associated antigen. Int J Cancer (1981) 0.86
Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem (1998) 0.86
MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats. Cancer Res (1998) 0.86
Role of the major histocompatibility complex in resistance to Marek's disease: restriction of the growth of JMV-MD tumor cells in genetically resistant birds. Adv Exp Med Biol (1977) 0.86
Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res (1991) 0.85
Nomenclature for chicken MHC (B) antigens defined by monoclonal antibodies. Immunogenetics (1981) 0.85
Histamine-induced suppressor factor (HSF): inhibition of helper T cell generation and function. J Immunol (1983) 0.85
Probing the conformational and dynamical effects of O-glycosylation within the immunodominant region of a MUC1 peptide tumor antigen. J Pept Res (2003) 0.85
Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int Immunol (1998) 0.84
Natural and acquired antibodies to Plasmodium lophurae in intact and bursaless chickens. I. Agglutination and passive immunity studies. J Parasitol (1969) 0.84
Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. J Immunother (1997) 0.84
Characterization of monoclonal antibodies to carcinoembryonic antigen with increased tumor specificity. Lab Invest (1986) 0.83
Genetic control of resistance to Marek's disease. IARC Sci Publ (1978) 0.83
Monoclonal antibodies directed against a widespread oncofetal antigen: the alpha-fetoprotein receptor. Tumour Biol (1993) 0.83
A monoclonal antibody against chicken MHC class I (B-F) antigens. Immunogenetics (1985) 0.83
Radioiodinated peanut lectin: clinical use as a tumour-imaging agent and potential use in assessing renal-tubular function. Eur J Nucl Med (1986) 0.83
Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother (1999) 0.82
Radioimmunoassay of carcinoembryonic antigen. Methods Enzymol (1982) 0.82
Carbohydrate groups in the major glycoprotein of Rous sarcoma virus. Nature (1974) 0.82
Restricted expression of an MHC alloantigen in cells of the erythroid series: a specific marker for erythroid differentiation. J Supramol Struct (1980) 0.82
A sensitive Autoanalytical method for sialic acids. Anal Biochem (1975) 0.81
Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides. Glycoconj J (1995) 0.81
The graft-versus-host reaction to minor alloantigens. Cell Immunol (1973) 0.81
Association of MUC-1 and SPGL-1 with low-density microdomain in T-lymphocytes: a preliminary note. Biochem Biophys Res Commun (2001) 0.81
Clinical evaluation of a new two-site assay for CA125 antigen. Int J Biol Markers (1991) 0.81
Antigenic heterogeneity of human colorectal cancer cell lines analyzed by a panel of monoclonal antibodies. I. Heterogeneous expression of Ia-like and HLA-like antigenic determinants. J Natl Cancer Inst (1982) 0.80
The high background immune reactivity of mice to polymorphic determinants on xenogeneic erythrocytes: theoretical and practical implications. J Immunol (1982) 0.80
Selection for virulence and organ-specific metastasis of herpesvirus-transformed lymphoma cells. Int J Cancer (1980) 0.80
Preference of the early murine immune response for polymorphic determinants on human lymphoid-leukemia cells and the potential use of monoclonal antibodies to these determinants in leukemia-typing panel. Oncodev Biol Med (1982) 0.80